TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01046058

Recruitment Status : Completed

First Posted : January 11, 2010

Last Update Posted : October 14, 2013

Sponsor:

Information provided by (Responsible Party):

Tibotec Pharmaceuticals, Ireland

Study Description

Brief Summary:

The purpose of the study is to investigate the effect of moderate and severe hepatic impairment on the pharmacokinetics of TMC435. Pharmacokinetics means how the drug is absorbed into the bloodstream, distributed in the body and eliminated from the body. In addition, the short-term safety and tolerability of TMC435 in participants with hepatic impairment will be determined. The results of this study will guide dose recommendations for TMC435 in patients with impaired liver function.

Condition or disease	Intervention/treatment	Phase
Hepatitis C Virus	Drug: TMC435	Phase 1

Detailed Description:

This is a Phase I, open-label trial to investigate the pharmacokinetics (how the drug is absorbed into the bloodstream, distributed in the body and eliminated from the body) of TMC435 in 8 participants with moderate hepatic impairment and 8 participants with severe hepatic impairment as compared to 8 participants with normal hepatic function, matched for age, gender, race, BMI (body mass index = weight in kilogram divided by square of height in meters) and smoking status. Open-label means that the study doctor and the participants know what treatment will be assigned to them. All participants will receive 150 mg of TMC435 by mouth for 7 days. Participants with severe hepatic impairment will be treated when the pharmacokinetic profiles of TMC435 in participants with moderate hepatic impairment have been evaluated. The dose of TMC435 may be changed for participants with severe hepatic impairment after evaluation of the blood levels TMC435 in participants with moderately impaired hepatic function. Tolerability and safety of TMC435 will be assessed throughout the trial period. Illnesses and side effects will be checked at every visit. Blood samples will be taken at screening, on the day before TMC435 intake, on days 2, 3, 5, 6, 7 (11 times), 8 and 9 and at 2 follow-up visits. Blood levels of TMC435 will be determined on days 2, 5, 6, 7, 8 and 9. Urine samples, ECG and vital signs will be taken at screening, twice on day 7 and at 2 follow-up visits. A physical examination will be done at screening, on the day before TMC435 intake, on day 9 and at both follow-up visits. All participants will receive a 150 mg dose of TMC435 for 7 days, given by mouth as 2 capsules of 75 mg. After evaluation of the pharmacokinetic profiles of TMC435 in participants with moderate hepatic impairment, the dose may be changed for participants with severe hepatic impairment.

Study Design


Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	23 participants
Allocation:	Non-Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	A Phase I, Open-label, Sequential Trial to Investigate the Pharmacokinetics, Safety, and Tolerability of TMC435 in Subjects With Moderately or Severely Impaired Hepatic Function
Study Start Date :	January 2010
Actual Primary Completion Date :	July 2011
Actual Study Completion Date :	July 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Simeprevir

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Panel A: TMC435 150 mg Participants enrolled in Panel A had moderate hepatic failure and received TMC435 150 mg once daily for 7 days.	Drug: TMC435 150 mg (two 75-mg capsules) orally (by mouth) once daily for 7 days
Experimental: Panel B: TMC435 150 mg Participants enrolled in Panel B had severe hepatic impairment and received TMC435 150 mg once daily for 7 days after the safety of TMC435 150 mg once daily for 7 days was evaluated in participants enrolled in Panel A.	Drug: TMC435 150 mg (two 75-mg capsules) orally (by mouth) once daily for 7 days

Outcome Measures

Primary Outcome Measures :

Pharmacokinetic profile of TMC435 in patients with moderate and severe hepatic impairment [ Time Frame: Measured at 16 predefined time points over a period of 9 days. Extensive analysis is planned on Day7 (after last intake of TMC435), with 12 PK sampling moments over 48 hours. ]

Secondary Outcome Measures :

Short-term safety and tolerability of TMC435 in volunteers with moderate or severe hepatic impairment [ Time Frame: AEs monitored each visit; vital signs, urinalysis and ECG parameters on Day 7 and on both follow-up visits; Safety blood sample at 6 predefined timepoints (over 5 days) and on both follow-up visits. ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Participants with hepatic impairment: Moderate or severe hepatic impairment, clinically diagnosed as Child Pugh B or C
Stable liver cirrhosis and hepatic impairment for at least 3 months prior to the start of the study. Participants with normal hepatic function: Healthy based on a medical evaluation including medical history, physical examination, blood tests and electrocardiogram

Exclusion Criteria:

Participants with hepatic impairment: Fluctuating or rapidly deteriorating hepatic function as indicated by widely varying or worsening of clinical and/or laboratory signs of hepatic impairment within 3 months prior or within the screening period
Cirrhosis due to chronic hepatitis B or C infection. Participants with normal hepatic function: History or presence of hepatic disease

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01046058

Locations


United States, California

Anaheim, California, United States
United States, Florida

Orlando, Florida, United States
United States, Texas

San Antonio, Texas, United States

Sponsors and Collaborators

Tibotec Pharmaceuticals, Ireland

Investigators


Study Director:	Tibotec Pharmaceuticals Clinical Trial	Tibotec Pharmaceutical Limited

More Information

Additional Information:

A Phase I, open-label, sequential trial to investigate the pharmacokinetics, safety, and tolerability of TMC435 in subjects with moderately or severely impaired hepatic function This link exits the ClinicalTrials.gov site

This link exits the ClinicalTrials.gov site


Responsible Party:	Tibotec Pharmaceuticals, Ireland
ClinicalTrials.gov Identifier:	NCT01046058 History of Changes
Other Study ID Numbers:	CR016783 TMC435-TiDP16-C113 ( Other Identifier: Tibotec Pharmaceuticals, Ireland )
First Posted:	January 11, 2010 Key Record Dates
Last Update Posted:	October 14, 2013
Last Verified:	October 2013

Keywords provided by Tibotec Pharmaceuticals, Ireland:


TMC435-TiDP16-C113 TMC435-C113 TMC435	HCV Protease Inhibitor Hepatitis C

Additional relevant MeSH terms:


Hepatitis Hepatitis C Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Flaviviridae Infections	RNA Virus Infections Simeprevir Antiviral Agents Anti-Infective Agents Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action

To Top